| # | Drug | Count |
|---|---|---|
| 0 | ADALIMUMAB | 190 |
| 1 | INFLIXIMAB | 110 |
| 2 | BEVACIZUMAB | 95 |
| 3 | PREDNISONE | 86 |
| 4 | AZATHIOPRINE | 81 |
| 5 | METRONIDAZOLE | 60 |
| 6 | VEDOLIZUMAB | 60 |
| 7 | ADALIMUMAB-AATY | 55 |
| 8 | ADALIMUMAB-ADAZ | 55 |
| 9 | ADALIMUMAB-FKJP | 55 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | A AND D OINTMENT | 1 | 0.1667 |
| 1 | SALINE LAXATIVE | 1 | 0.1250 |
| 2 | PYRIMETHAMINE | 12 | 0.0094 |
| 3 | PAROMOMYCIN SULFATE | 1 | 0.0094 |
| 4 | METHENAMINE, SODIUM PHOSPHATE, MONOBASIC, METHYLENE BLUE, AND HYOSCYAMINE SULFATE | 1 | 0.0090 |
| 5 | INFLIXIMAB-DYYB | 26 | 0.0075 |
| 6 | DEXTROSE AND SODIUM CHLORIDE | 1 | 0.0060 |
| 7 | FLOXURIDINE | 1 | 0.0058 |
| 8 | SORBITOL | 3 | 0.0050 |
| 9 | EPHEDRINE SULFATE | 1 | 0.0046 |
| # | Drug class | Count |
|---|---|---|
| 0 | Tumor Necrosis Factor Blocker [EPC] | 180 |
| 1 | Corticosteroid [EPC] | 161 |
| 2 | Vascular Endothelial Growth Factor Inhibitor [EPC] | 102 |
| 3 | Platinum-based Drug [EPC] | 92 |
| 4 | Purine Antimetabolite [EPC] | 81 |
| 5 | Nucleoside Metabolic Inhibitor [EPC] | 77 |
| 6 | Integrin Receptor Antagonist [EPC] | 69 |
| 7 | Nonsteroidal Anti-inflammatory Drug [EPC] | 69 |
| 8 | Nitroimidazole Antimicrobial [EPC] | 60 |
| 9 | GLP-2 Analog [EPC] | 52 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Dihydrofolate Reductase Inhibitor Antimalarial [EPC] | 12 | 0.0094 |
| 1 | GLP-2 Analog [EPC] | 52 | 0.0039 |
| 2 | Antiseptic [EPC] | 10 | 0.0023 |
| 3 | Provitamin D2 Compound [EPC] | 31 | 0.0010 |
| 4 | Nitroimidazole Antimicrobial [EPC] | 60 | 0.0009 |
| 5 | Purine Antimetabolite [EPC] | 81 | 0.0008 |
| 6 | CD33-directed Immunoconjugate [EPC] | 3 | 0.0008 |
| 7 | Bile Acid Sequestrant [EPC] | 10 | 0.0008 |
| 8 | Integrin Receptor Antagonist [EPC] | 69 | 0.0008 |
| 9 | Echinocandin Antifungal [EPC] | 5 | 0.0006 |